ASH 2022

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL

Presented By

Dr Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN E1910

Conference

ASH 2022

15 December, 2022 11:26

Novel therapy may replace standard-of-care prophylaxis for GVHD

Presented By

Dr Shernan Holtan, University of Minnesota, MN, USA

Trial

Phase 3, BMT CTN 1703

Conference

ASH 2022

15 December, 2022 11:24

High-dose chemotherapy plus ASCT superior to standard immune-chemotherapy in primary CNS lymphoma

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

15 December, 2022 11:23

Odronextamab scores in relapsed/refractory diffuse large B-cell lymphoma

Presented By

Dr Won-Seog Kim, Samsung Medical Center, South Korea

Trial

Phase 2, ELM-2

Conference

ASH 2022

15 December, 2022 11:21

LMWH does not result in higher live birth rates in women with inherited thrombophilia

Presented By

Prof. Saskia Middeldorp, Radboud UMC, the Netherlands

Trial

ALIFE2

Conference

ASH 2022

15 December, 2022 11:20

Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care

Presented By

Prof. Régis de Latour, Saint-Louis Hospital, Paris, France

Trial

Phase 3, Apply-PNH

Conference

ASH 2022

15 December, 2022 11:19

Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial

Presented By

Dr Nizar Bahlis, University of Calgary, Canada

Trial

Phase 3, MagnetisMM-3

Conference

ASH 2022

14 December, 2022 10:53

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?

Trial

Phase 3, ASAP

Conference

ASH 2022

14 December, 2022 10:52

Excellent results for triplet regimen in FLT3-mutated AML

Presented By

Dr Nicholas Short, University of Texas, TX, USA

Trial

Phase 1/2

Conference

ASH 2022

14 December, 2022 10:51

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML

Presented By

Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

14 December, 2022 10:50

CAR-hematotox score predicts toxicity, infections, and clinical outcomes in MCL

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

14 December, 2022 10:49

Deep and durable responses for quadruple therapy in smouldering MM

Presented By

Dr Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, ASCENT

Conference

ASH 2022

14 December, 2022 10:48

Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma

Presented By

Prof. Martin Dreyling, University Hospital Munich, Germany

Trial

Phase 3, Triangle

Conference

ASH 2022

13 December, 2022 11:33

Efgartigimod successful in immune thrombocytopenia

Presented By

Dr Catherine Broome, Georgetown University, DC, USA

Trial

Phase 3, ADVANCE

Conference

ASH 2022

13 December, 2022 11:32

Promising results for triplet therapy with magrolimab in AML

Presented By

Dr Naval Daver, Anderson Cancer Center, TX, USA

Conference

ASH 2022

13 December, 2022 11:30

Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data

Presented By

Prof. Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1/2, MonumenTAL-1

Conference

ASH 2022

13 December, 2022 11:29

High-dose methotrexate or standard interim maintenance in young patients with ALL?

Presented By

Amy Kirkwood, University College London, UK

Trial

Phase 3, UKALL 2011

Conference

ASH 2022

13 December, 2022 11:28

Ibrutinib plus venetoclax displays long-term benefits in CLL

Presented By

Dr John Allan, Weill Cornell Medicine, NY, USA

Conference

ASH 2022

13 December, 2022 11:26